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Abstract: We investigated the efficacy of Ligusticum wallichi aqueous extract (LWE) for 
myocardial protection against ischemia-reperfusion injury. Rats were fed for five weeks 
with either a control diet (sham and ischemia reperfusion (IR) model control groups) or a 
diet mixed with 0.2%, 0.4% or 0.6% Ligusticum wallichi extract. At the end of the five 
week period, hearts were excised and subjected to global ischemia for 30 min followed by 
reperfusion for 2 h. The hearts were compared for indices of oxidative stress and immunity 
activities.  Administration  of  Ligusticum  wallichi  extract  significantly  decreased  serum 
TNF-α, IL-6, IL-8, NO, MIP-1α, CRP and myocardium MDA levels, and serum CK, LDH 
and AST activities, and increased myocardium Na
+-K
+-ATPase, Ca
2+-Mg
2+-ATPase, NOS, 
SOD, CAT, GSH-Px and TAOC activities. The results indicate that Ligusticum wallichii 
extract  treatment  can  enhance  myocardial  antioxidant  status  and  improve  the  immunity 
profile in ischemic-reperfusion rats. 
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1. Introduction 
Ligusticum wallichi, a popular Chinese herbal medicine, has been used orally with other herbs for 
―heart disease‖  for thousands  of years [1]. Current  research in  nutrition  science provides a better 
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understanding of the possible link between the plant and heart disease. A component (ligustrazine) of 
Ligusticum wallichi increases myocardial contractility and coronary circulation [2,3]. In contrast, this 
plant can inhibit the muscle contractions induced by vasoconstrictors and low systemic blood pressure [4]. 
However, little is known about the effects of Ligusticum wallichi on the contraction of smooth muscle 
and the mechanisms underlying the contractile system. 
Cardiovascular disease, particularly ischemic heart disease (IHD), has become a worldwide health 
problem affecting all economic groups of the society. Oxygen derived free radicals have been credited 
with playing an important role in the genesis of tissue injury during ischemia and reperfusion of the 
heart  [5,6].  There  is  indeed  substantial  evidence  that  reactive  oxygen  species  (ROS)  such  as  the 
superoxide anion, hydrogen peroxide, and hydroxyl radical are responsible for the myocardial injury 
during ischemia-reperfusion [7–9]. Furthermore, exogenously administrated free radical scavengers 
are known to enhance the functional recovery of the ischemic-reperfused heart [10–12]. In tissues, 
protective mechanisms such as physiological endogenous antioxidants are present to minimize tissue 
injury by oxygen derived free radicals [13]. Since these endogenous antioxidants protect against free 
radical attack, observing the alterations in their content and redox status may enable us to elucidate the 
mechanism of how the antioxidant defense system is effective against the ischemia-reperfusion injury. 
This may lead to the efficient therapeutic use of exogenous antioxidants. Myocardial damage induced 
by ischemia-reperfusion is due, at least in part, to the generation of ROS [14–18]. Evidence supporting 
ROS as a culprit of myocardial ischemia reperfusion (IR) injury came from several direct and indirect 
observations. There have been reports showing a close correlation between the production of ROS and 
simultaneous consumption of endogenous antioxidants [19–22]. 
It is now well established that many immune cells produce free radicals as a means of host defense 
and pathogen killing. As such, infiltration of activated immune cells into cardiac muscle is a potential 
mechanism  of  cardiac  oxidant  production.  Interleukin-10  (IL-10)  is  a  cytokine  with  pleiotropic 
properties  [23].  Several  lines  of  evidence  suggest  that  IL-10  may  have  a  therapeutic  potential  in 
atherosclerosis, but its mechanisms of action have not been clarified [24]. The anti-inflammatory and 
anti-atherogenic properties of IL-10 have been demonstrated using several models of atherosclerosis in 
mice [25]. In humans, the expression of IL-10 has been demonstrated in both coronary arteries and 
atherosclerotic plaque [26]. IL-10 inhibits synthesis of various cytokines (including IL-1, IL-1β, TNF-α,  
IL-6, and IL-8) by stimulated monocyte/macrophages, suppressing the inflammatory response [27]. 
Recently, much interest has been focused on the potential pivotal role that IL-10 plays in myocardial 
ischemia and reperfusion (MI/R) [28]. 
Pro-inflammatory cytokines and immune cell activation are modulators of cardiovascular function 
by  a  variety  of  mechanisms,  including  the  generation  of  oxygen-derived  free  radicals  and  the 
production of NO [29]. It has been suggested that nitric oxide (NO) plays a protective role in ischemia 
and  reperfusion  by  quenching  the  effects  of  superoxide  (and  other  ROS)  on  mitochondrial  Ca
2+ 
homeostasis [30]. NO is synthesized by nitric oxide synthase (NOS), and the three different isoforms 
include  endothelial  NOS (eNOS),  neuronal NOS (nNOS) and  inducible NOS (iNOS)  [31]. In  the 
cardiovascular system, the major activity presents in endothelial cell is eNOS [32]. 
An emerging area in cardiovascular research is the apparent significance of biological oxidation 
mechanisms. Many recent studies have suggested that oxygen-derived free radicals may be important 
participants in a wide array of cardiac conditions, and several clinical trials evaluating the use of Int. J. Mol. Sci. 2011, 12                       
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antioxidants as therapeutics either have already been conducted or are underway. The present study 
was  designed  to  investigate  the  effects  of  the  administration  of  Ligusticum  wallichii  extract  on 
endogenous antioxidant status and immunity activities in ischemic reperfusion rats. 
2. Material and Methods 
2.1. Material 
Ligusticum wallichii was purchased from a local herb shop in Shanghai city, China. 
2.2. Preparation of Ligusticum wallichii Extract 
A batch of 100 g of the Ligusticum wallichii powder was loaded in a 500 mL cellulose paper (number 
4) timber of the Soxhlet extractor with 1000 mL flask and continuously extracted using deionized 
water at boiling point from 2 to 24 h. Every experiment was executed in duplicate. Then, all these 
extracts were collected, filtered, concentrated, dried and weighed.  
2.3. Experimental Procedure 
Forty male Wistar rats (aged 5 months) weighing 180–210 g were obtained from the Shanghai 
Iiaotong University and were housed at 25 ±  5 ° C under 12 h light and dark cycle. Experiments were 
carried out according to the guidelines of the animal ethics committee of the Institute. The rats were 
divided into 5 groups (sham-operation group (SO); I/R model group (IR); three Ligusticum wallichi 
aqueous extract (LWE)-treated groups). Three LWE-treated groups (n = 8 in each group) were fed 
with the Ligusticum wallichii extract in three doses (0.2 g/kg, 0.4 g/kg and 0.6 g/kg body weight) once 
a day by gavage technique for 5 weeks, along with standard rat chow and water, ad libitum. Sham-
operation group and model I/R group (n = 6 in each group) were fed with vehicle (distilled water) by 
oral gavage once a day for 5 weeks, along with standard rat chow and water, ad libitum. There was no 
significant difference in body weight of the treated rats, when compared with control, either at the 
beginning or at end of the study period. The treated rats did not offer any abnormal resistance to drug 
administration. The treatment schedule did not cause any change in food and water intake pattern. 
During oral gavage, one rat in the low dose LWE-treated group and two rats in high dose LWE-treated 
group died. 
After 48 h of the last dose, rats were anesthetized with ketamine 100 mg/kg (i.m.) and xylazine  
10 mg/kg (i.m.). The animals were ventilated with room air using a rodent respirator. The chest was 
opened by middle thoracotomy. After pericardiotomy, a 4–0 black silk ligature was placed under the 
left aortic descending coronary artery, and the ends of the tie were threaded through a small vinyl tube 
to  form  a  snare  for  reversible  left  aortic  descending  coronary  artery  occlusion.  After  30  min  of 
ischemia, the myocardium was reperfused by loosening the snare for 2 h. The heart temperature was 
monitored using a thermistor probe placed in the right ventricle wall and kept constant at 37 ° C during 
the stabilization and reperfusion periods and at 24 ° C during the ischemic period. Sham-operated 
animals underwent all the previously described surgical procedures apart from the fact that the suture 
passing around the left coronary artery was not tied (Sham I/R rats). All animals were maintained in 
accordance with the guidelines of the china Institutional Animal Care and Use Committee. Int. J. Mol. Sci. 2011, 12                       
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2.4. ECG ST-Segment Evaluation 
Electrocardiograms (ECG) were recorded continuously with standard lead II before, during and after 
myocardial ischemia and reperfusion (MIR) in all the animals by use of a computerized PowerLab 
system (ADInstruments, Australia). ST segment of ECG elevated over 100 μV from baseline was 
recruited as an index of ischemia. The amount of elevated voltage in μV in the different groups was 
compared statistically. 
2.5. Samples Preparation 
After 36 day of treatment, the animals were fasted overnight and then sacrificed under diethyl ether 
anesthesia. All blood and heart tissue samples were taken from the animals of all groups. The heart 
tissue was immediately washed with saline, blotted on filter paper, weighed and then cut into small 
pieces and homogenized in Tris–HCl buffer (0.025 M, pH 7.5) with a homogenizer to give a 10% (w/v) 
heart homogenate. The homogenate was then centrifuged at 12,000 rpm for 15 min and the supernatant 
obtained was frozen until use. Serums were separated from the blood samples and were stored at  
−70 ° C pending biochemical analyses. 
2.6. Biochemical Analysis 
Creatine  kinase  activity  was  measured  in  serum.  The  reaction  mixture  consisted  of  60  mM  
Tris–HCl, pH 7.5, containing 7 mM phosphocreatine, 9 mM MgSO4 and approximately 0.4–1.2 μg 
protein in a final volume of 100 μL. After 15 min of pre-incubation at 37 ° C, the reaction was started 
by the addition of 0.3 μmol of ADP plus 0.08 μmol of reduced glutathione. The reaction was stopped 
after  10  min  by  the  addition  of  1  μmol  of  p-hydroxymercuribenzoic  acid.  The  creatine  formed  
was  estimated  according  to  the  colorimetric  method  of  [33].  The  color  was  developed  by  the  
addition of 100 μL 2% α-naphtol and 100 μL 0.05% diacetyl in a final volume of 1 mL and read 
spectrophotometrically after 20 min at 540 nm.  
Lactate dehydrogenase (LDH) activity was measured by the method of Cabaud, Wroblewski and 
Ruggieri [34]. Pyruvic acid was used, in the presence of NADH as the substrate. 2,4-DNPH was added 
and the hydrazone formed was determined using a standard prepared from pyruvate buffer. 
Aspartate transaminase (AST) activity
 were analyzed by an automated analyzer (Olympus AU-600, 
Shizuoka-ken,
 Japan) using commercial kits (Olympus). 
Serum  TNF-α  level  was  measured  by  a  commercially  available  enzyme-linked  immunosorbent 
assay (ELISA) kit (rat TNF-α ELISA, ENDOGEN Inc., Woburn, MA, USA) (Sensitivity: <10 pg m
−1), 
according to the instructions of the manufacturer and plates were read at 450 nm wavelength by a 
spectrophotometer (ELx 808 Ultra Microplate Reader BIO-TEK Instruments Inc., USA). 
Levels of serum IL-6, IL-8 and IL-10 were measured with ELISA kits using monoclonal antibodies 
specific to rat IL-6, IL-8 and IL-10 (BioSource International Inc., California, USA).  
Levels of serum MIP-1α and CRP were measured with rat MIP-1 alpha ELISA/ EIA Kits and rat  
C-reactive protein (CRP) ELISA kit. 
NO levels in the plasma were determined by NO assay kit (Cayman Chemical, Ann Arbor, MI, 
USA). Fifty microliters of plasma was added to wells of ELISA micro plate followed by 10 μL of enzyme-Int. J. Mol. Sci. 2011, 12                       
 
 
1995 
cofactors and 10 μL of nitrate reductase mixture. Plate was covered and incubated for 3 h at room 
temperature. After incubation, 50 μL of Griess reagent 1 followed immediately by 50 μL of Griess 
reagent 2 was added. Plate was allowed to develop the color for 10 min at room temperature and 
absorbance was read at 540 nm using ELISA plate reader (Automated Microplate Reader, Model 
EL311, Bio-Tek Instruments, Inc., Winooski, VT, USA). 
The total NOS activity method is based on the diazotization of sulfanilic acid by NO at acid pH and 
subsequent coupling to N-(1-naphthyl-ethylenediamine) [35].  
The  concentration  of  MDA  in  the  10%  tissue  homogenates  (prepared  in  0.9%  NaCl)  was 
determined as thiobarbituric acid reactive substances (TBARS) according to Buege and Aust [36]. 
GSH was measured according to the method of Ellman [37]. 
Superoxide dismutase (SOD) activity was determined in tissue according to Sun et al. [38]. The 
method  is  based  on  inhibition  of  nitroblue  tetrazolium  (NBT)  reduction  by  the  xanthine-xanthine 
oxidase system as a superoxide generator. SOD activity was assessed in the ethanol phase of the 
myocardial homogenates after 1 mL ethanol/chloroform mixture (5/3, v/v) was added to the same 
volume of sample that was centrifuged. One unit of SOD was defined as the enzyme amount causing 
50% inhibition of the NBT reduction rate. SOD activity was expressed as U/mg protein.  
To determine the activity of catalase (CAT), 10% tissue homogenates, prepared in 0.9% NaCl, were 
centrifuged at 8500 ×  g at 4 ° C for 15 min. In the supernatant (after dilution with phosphate buffer,  
pH = 7.0), CAT activity was determined according to Aebi [39]. 
Glutathione peroxidase (GPx) activity was measured by the procedure of Flohe and Gunzler [40]. 
One milliliter of reaction mixture that contained 0.3 mL of phosphate buffer (0.1 M, pH 7.4), 0.2 mL 
of glutathione (GSH) (2 mM), 0.1 mL of sodium azide (10 mM), 0.1 mL of H2O2 (1 mM), and 0.3 mL 
of tissue supernatant was prepared. After incubation at 37 ° C for 15 min, reaction was terminated by 
addition of 0.5 mL 5% TCA. Tubes were centrifuged at 1500 g for 5 min and the supernatant was 
collected. To 0.1 mL of reaction supernatant, 0.2 mL of phosphate buffer (0.1 M, pH 7.4), and 0.7 mL 
of 5,5′dithio-bis-(2-nitrobenzoic acid) (DTNB, 0.4 mg/mL) were added. After mixing, absorbance was 
recorded at 420 nm. 
The level of TAOC was measured by the method of ferric reducing/antioxidant power assay [41]. 
The reaction mixture for Ca
2+-Mg
2+-ATPase and Na
+, K
+-ATPase assays contained 5.0 mM MgCl2, 
80.0 mM NaCl, 20.0 mM KCl and 40.0 mM Tris–HCl, pH 7.4, in a final volume of 200 μL. The 
reaction was initiated by addition of ATP to a final concentration of 3.0 mM. Ouabain-insensitive 
Ca
2+-Mg
2+-ATPase was assayed under the same conditions with addition of 1.0 mM ouabain. Na
+,  
K
+-ATPase activity was calculated by the difference between the two assays [42]. Released inorganic 
phosphate (Pi) was measured by the method of Chan et al. [43]. Specific activities of the enzymes 
were expressed as nmol Pi released per min per mg of protein. 
2.7. Statistical Analysis 
A one way-analysis of variance (ANOVA) was used to analyze statistical significance. Differences 
were  considered  statistically  significant  at  P  <  0.05.  Correlations  were  assessed  by  Pearson  
correlation coefficient. Int. J. Mol. Sci. 2011, 12                       
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3. Result 
3.1. Effects of Pretreatment with Ligusticum wallichii Extract on the ST Segment of ECG in Rats 
Subjected to Ischemia and Reperfusion 
Before ligation of the coronary artery, the values of ST-segment elevation in the SO, IR and three 
LWE groups were 40.9 ±  2.2, 42.1 ±  1.9, 41.3 ±  2.4, 40.4 ±  2.2, and 43.4 ±  2.8 μV, respectively, 
indicating that there was no significant difference in elevation of ST segment among the three groups 
before ischemia. The values of the ST segment in the IR group 30 min after ischemia and 10 min after 
reperfusion  were  increased,  respectively,  to  177.4  ±   9.2  and  123.3  ±   5.3  μV,  which  were  both 
significantly different from 49.7 ±  2.6 and 46.2 ±  3.1 μV in the SO group. It is interesting that in the three 
LWE groups the values of the ST segment were 152.5 ±  6.3 (0.6%), 145.2 ±  5.1 (0.4%), 124.7 ±  5.9 
(0.2%) and 101.1 ±  6.4 (0.6%), 87.9 ±  5.3 (0.4%), 68.6 ±  3.8 μV (0.2%), respectively, at the same 
recording time points as above, showing a significant attenuation in the elevation of the ST segment in 
comparison with the corresponding values in the IR group. 
3.2. Effect of Ligusticum wallichii Extract on Serum CK, LDH and AST Activities 
The effect of Ligusticum wallichii extract on serum CK, LDH and AST activities is shown in Figure 1. 
The activities of serum CK, LDH and AST were significantly increased in the IR model rats when 
compared with the SO control group. However, that alternation was significantly reduced (P < 0.05) by 
feeding Ligusticum wallichii extract when compared with the IR model rats.  
Figure 1. Effect of Ligusticum wallichii extract on serum CK, LDH and AST activities. 
b P < 0.01 compared with SO control group; 
d P < 0.01 compared with IR model group. 
Group 1: sham operation (SO); group 2: ischemia reperfusion (IR); group 3: Ligusticum 
wallichii extract (LWE) 0.2 g/kg body weight; group 4: LWE 0.4 g/kg body weight; group 
5: LWE 0.6 g/kg body weight. 
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3.3. Effect of Ligusticum wallichii Extract on Serum MIP-1α and CRP Levels  
The effect of Ligusticum wallichii extract on serum MIP-1α and CRP levels is shown in Figure 2. The 
levels of serum MIP-1α and CRP were significantly enhanced by IR operation treatment in comparison 
with the SO control rats. Similarly, administration of the Ligusticum wallichii extract (0.2%, 0.4% and 
0.6%) significantly reduced serum MIP-1α and CRP levels in a dose-dependent manner. 
Figure 2. Effect of Ligusticum wallichii extract on serum CRP (A) and MIP-1α (B) levels. 
b P < 0.01 compared with SO control group; 
d P < 0.01 compared with IR model group. 
Group 1: sham operation (SO); group 2: ischemia reperfusion (IR); group 3: Ligusticum 
wallichii extract (LWE) 0.2 g/kg body weight; group 4: LWE 0.4 g/kg body weight; group 
5: LWE 0.6 g/kg body weight. 
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3.4. Effect of Ligusticum wallichii Extract on Serum TNF-α, IL-6, IL-8 and Myocardium IL-10 Levels 
The effects of Ligusticum wallichii extract on serum TNF-α, IL-6, IL-8 and myocardium IL-10 
levels is shown in Figure 3. The levels of serum TNF-α, IL-6, IL-8 and myocardium IL-10 were 
significantly increased by IR operation treatment in comparison with the SO control rats. Similarly, 
administration of the Ligusticum wallichii extract (0.2%, 0.4% and 0.6%) significantly reduced the 
serum TNF-α, IL-6, IL-8 and myocardium IL-10 levels in a dose-dependent manner.  
3.5. Effect of Ligusticum wallichii AExtract on Serum NO Level and Myocardium NOS Activity 
The effects of Ligusticum wallichii extract on serum NO level and myocardium NOS activity is 
shown in Figure 4. Serum NO level and myocardium NOS activity were significantly reduced by IR 
operation treatment in comparison with the SO control rats. In contrast to the findings in IR model rats, 
there  was  a  significant  decrease  in  the  serum  NO  level  and  myocardium  NOS  activity  when  the 
Ligusticum wallichii extract was administered to IR rats at all 3 dose levels studied. 
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Figure 3. Effect of Ligusticum wallichii extract on serum TNF-α (A), IL-6 (B), IL-8 (C) 
and myocardium IL-10 (D) levels.
 b P < 0.01 compared with SO control group; 
d P < 0.01 
compared  with  IR  model  group.  Group  1:  sham  operation  (SO);  group  2:  ischemia 
reperfusion (IR); group 3: Ligusticum wallichii extract (LWE) 0.2 g/kg body weight; group 4: 
LWE 0.4 g/kg body weight; group 5: LWE 0.6 g/kg body weight. 
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3.6. Effect of Ligusticum wallichii Extract on Myocardium MDA and GSH Levels 
Compared with the SO rats, the myocardium MDA concentration was markedly higher in the IR 
model rats,  whereas  myocardium GSH level was significantly  lower in  IR model rats  (Figure  5). 
Ligusticum wallichii extract treatment significantly lowered myocardium MDA and enhanced GSH 
levels when compared with IR model group. 
3.7. Effect of Ligusticum wallichii Extract on Myocardium SOD, CAT, GSH-Px and TAOC Activities 
Compared with the SO rats, the myocardium SOD, CAT, GSH-Px and TAOC activities were markedly 
lower in IR model rats (Figure 6). Treatment of the animals with Ligusticum wallichii extract (0.2%, 
0.4%  and  0.6%)  significantly  enhanced  the  decrease  of  myocardium  SOD,  CAT,  GSH-Px  and  
TAOC activities.  
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Figure  4.  Effect  of  Ligusticum  wallichii  extract  on  serum  NO  level  and  myocardium  
NOS activity. 
b P < 0.01 compared with SO control group; 
d P < 0.01 compared with IR 
model group. Group 1: sham operation (SO); group 2: ischemia reperfusion (IR); group 3: 
Ligusticum wallichii extract (LWE) 0.2 g/kg body weight; group 4: LWE 0.4 g/kg body 
weight; group 5: LWE 0.6 g/kg body weight. 
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Figure 5. Effect of Ligusticum wallichii extract on myocardium MDA and GSH levels.  
b P < 0.01 compared with SO control group; 
d P < 0.01 compared with IR model group. 
Group 1: sham operation (SO); group 2: ischemia reperfusion (IR); group 3: Ligusticum 
wallichii extract (LWE) 0.2 g/kg body weight; group 4: LWE 0.4 g/kg body weight; group 
5: LWE 0.6 g/kg body weight. 
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Figure 6. Effect of Ligusticum wallichii extract on myocardium SOD, CAT, GSH-Px and 
TAOC activities.
 b P < 0.01 compared with SO control group; 
d P < 0.01 compared with IR 
model group. Group 1: sham operation (SO); group 2: ischemia reperfusion (IR); group 3: 
Ligusticum wallichii extract (LWE) 0.2 g/kg body weight; group 4: LWE 0.4 g/kg body 
weight; group 5: LWE 0.6 g/kg body weight. 
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Figure  7.  Effect  of  Ligusticum  wallichii  extract  on  myocardium  Na
+-K
+-ATPase  and  
Ca
2+-Mg
2+-ATPase  activities.
  b P  <  0.01  compared  with  SO  control  group; 
d P  <  0.01 
compared  with  IR  model  group.  Group  1:  sham  operation  (SO);  group  2:  ischemia 
reperfusion (IR); group 3: Ligusticum wallichii extract (LWE) 0.2 g/kg body weight; group 
4: LWE 0.4 g/kg body weight; group 5: LWE 0.6 g/kg body weight. 
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3.8. Effect of Ligusticum wallichii Extract on Myocardium Na
+-K
+-ATPase and Ca
2+-Mg
2+-ATPase 
Activities 
The effect of Ligusticum wallichii extract on myocardium Na
+-K
+-ATPase and Ca
2+-Mg
2+-ATPase 
activities is shown in Figure 7. The activities of myocardium Na
+-K
+-ATPase and Ca
2+-Mg
2+-ATPase 
were  significantly  reduced  by  IR  operation  treatment  in  comparison  with  the  SO  control  rats. Int. J. Mol. Sci. 2011, 12                       
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Similarly,  administration  of  the  Ligusticum  wallichii  extract  (0.2%,  0.4%  and  0.6%)  significantly 
enhanced the myocardium Na
+-K
+-ATPase and Ca
2+-Mg
2+-ATPase activities in a dose-dependent manner.  
4. Discussion 
Acute myocardial infarction (AMI) is a common cause for hospital admission to acute geriatric 
units. The diagnosis of AMI is difficult in the elderly because they often present with non-specific 
clinical features or may be unable to give an accurate history because of confusion, dementia, or 
dysphasia [44]. Consequently AMI may be diagnosed on the basis of raised cardiac enzyme activities. 
Serum CK, AST and LDH are well known markers of myocardial infarction. When myocardial 
cells are damaged or destroyed due to deficient oxygen supply or glucose, the cardiac membrane 
becomes permeable or may rupture, resulting in leakage of enzymes. These enzymes enter into the 
blood stream thus increasing their concentration in the serum [45]. Activities of these enzymes in 
serum decreased in Ligusticum wallichii extract pretreated IR rats probably due to the protective effect 
of  Ligusticum  wallichii  extract  on  myocardium,  which  reduced  the  extent  of  myocardial  damage 
induced by IR, thereby restricting the leakage of these enzymes from myocardium. 
For several decades it has been known that the inflammatory response during reperfusion is the 
major cause of myocardial I/R injury. TNF-α is a potent cytokine which is elevated in a variety of 
inflammatory conditions. Endogenous TNF-α has been correlated with the deterioration of myocardial 
performance, while blockade of TNF-α with a neutralizing antibody preserves myocardial function 
after  IR  [46].  Interleukin  6  is  a  strong  chemoattractant  and  may  lead  to  the  infiltration  and 
consequential activation of leukocytes [47]. The protective effect of IL 10 in the outcome of IR injury 
has been suggested by several authors. Production of endogenous IL 10 is part of a natural anti-
inflammatory  response  that  limits  the  deleterious  effects  of  the  proinflammatory  cascade  after  
IR [48,49]. In our IR model, we observe significant increase in serum TNF-α, IL-6, IL-8 and decrease 
in myocardium IL-10 levels as compared with the SO control group. This indicated that immunity 
activities were markedly reduced in IR rats. Serum IL-6, TNF-α and IL-8 production was significantly 
decreased  in  LWE-treated  animals.  However,  myocardium IL-10 level was markedly  increased  in 
LWE-treated animals. We can adhere to the hypothesis that Ligusticum wallichii extract promotes  
IL-10 production, which in turn inhibits cytokine synthesis of IL-6, IL-8 and TNF-α. In addition, 
because  IL-10  production  could  be  protective  against  the  effects  of  reactive  oxygen  species,  this 
cytokine could be useful in the prevention of IR.  
Oxygen  free  radicals  are  known  to  been  generated  during  periods  of  ischemia  followed  by 
reperfusion.  Studies  on  the  antioxidant  changes  and  their  significance  during  heart  failure  have 
provided a new insight about the pathogenesis of heart disease.  
Nitric oxide (NO) is an important signaling molecule with vasodilatory, anti-inflammatory, and  
anti-platelet activities [50,51]. Numerous studies have shown both beneficial and harmful effects of 
NO on the cardiovascular system. NO is a free radical itself and can also form peroxynitrite, a potent 
oxidant that can potentially cause membrane lipid peroxidation leading to myocardial dysfunction. In 
contrast, NO relaxes vascular smooth muscle and could be cardioprotective against I–R injury through 
coronary vasodilatation and reduction of myocardial oxygen consumption via upregulation of cGMP. 
In this study, Ligusticum wallichii extract treatment enhanced serum NO level and myocardium NOS Int. J. Mol. Sci. 2011, 12                       
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activity. We suppose that the up-regulatory effect of Ligusticum wallichii extract on NO levels occurs 
through either activation of endothelium nitric oxide synthase (NOS) or by removing O2
− and thereby 
inhibiting consumption of NO.  
The biochemical profile of the myocardium, like depletion of SOD, catalase and glutathione (GSH) 
with  increase  TBARS,  provides  strong  evidence  for  oxidative  stress  occurring  during  ischemia-
reperfusion.  In  the  present  experiment,  increased  MDA  level  and  decreased  antioxidant  enzymes’ 
activities (SOD, CAT, GSH-Px and TAOC) were detected in IR rats. This indicated that oxidative 
injury  was  closely  associated  with  myocardium  ischemia-reperfusion.  Interestingly,  in  the  present 
study  the  hearts  from  Ligusticum  wallichii  extract  treated  groups  show  a  significant  decrease  in 
myocardial MDA as well as endogenous antioxidants (GSH, SOD, and CAT). This indicates that 
Ligusticum wallichii extract can reduce IR-induced oxidative injury by increasing antioxidant enzymes 
like SOD, catalase, GSH-Px and TAOC activities in LWE-treated groups.  
Na
+  overload  and  secondary  Ca
2+  influx  via  Na
+/Ca
2+  exchanger
  are  key  mechanisms  in 
cardiomyocyte  contracture  and  necrosis
  during  reperfusion.  The  Na
+-K
+-ATPase  catalyzes  ATP 
hydrolysis to supply energy required to drive the sodium pump, which is responsible for establishing 
and maintaining the electrochemical gradient for Na
+ and K
+ ions across the plasma membrane of 
mammalian cells. In the heart, the Na
+-K
+-ATPase has additional importance as the target for cardiac 
glycosides. By blocking the catalytic activity of the enzyme, cardiac glycosides increase [Na
+]i at least 
locally, which leads to an increased [Ca
2+]i (via Na
+-Ca
2+-exchanger). Ca
2+-ATPase and Mg
2+-ATPase 
have similar effect on [Ca
2+]i [52]. In the present study, it was found that myocardial Na
+-K
+-ATPase 
and Ca
2+-Mg
2+-ATPase activities were remarkably decreased. Ligusticum wallichii extract treatment 
could increase  myocardium Na
+-K
+-ATPase and Ca
2+-Mg
2+-ATPase activities in IR rats. Ischemic 
preconditioning (IP) has been shown to attenuate
 intracellular Na
+ accumulation and Ca
2+ overload 
during  ischemia
 and  reperfusion,  both  of  which  are  closely  related  to  the  outcome
 of  myocardial 
damage. LWE may produce beneficial effects by attenuating the remodeling of Na
+-K
+-ATPase and 
changes  in  Na+/Ca
2+  exchanger  in  hearts  after  I/R.  These  observations  indicate  that  Ligusticum 
wallichii extract treatment can enhance myocardial antioxidant status and improve immunity profile 
and reduce myocardium damage in ischemic-reperfusion rats. The ischemic insult activates Kupffer 
cells, and to a lesser degree endothelial cells and hepatocytes, leading to the formation of reactive 
oxygen  species  and  secretion  of  proinflammatory  cytokines/chemokines  [53,54].  Oxidative  stress 
directly  damages  endothelial  cells  and  hepatocytes,  while  the  soluble  factors  are  responsible  for 
neutrophil,  monocyte,  and  T  cell,  recruitment.  In  the  present  study,  we  supposed  that  improved 
immunity profile in ischemic-reperfusion rats may be achieved by antioxidant activities of Ligusticum 
wallichii extract. 
5. Conclusion 
In conclusion, the present study shows that the Ligusticum wallichii extract strongly reduced serum CK, 
LDH and AST activities, NO, TNF-α, IL-6, and IL-8 levels, and increased myocardial Na
+-K
+-ATPase, 
Ca
2+-Mg
2+-ATPase,  NOS,  SOD,  CAT,  GSH-Px  and  TAOC  activities  in  an  in  vivo  rat  model  
of cardiac ischemia–reperfusion. These results indicate that Ligusticum wallichii extract can enhance  Int. J. Mol. Sci. 2011, 12                       
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myocardial  antioxidant  status  and  improve  the  immunity  profile  and  reduce  myocardium  damage  in  
ischemic-reperfusion rats.  
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